Skip to main content
Top
Published in: Diabetologia 4/2011

01-04-2011 | Short Communication

Effects of a lifestyle intervention in metabolically benign and malign obesity

Authors: K. Kantartzis, J. Machann, F. Schick, K. Rittig, F. Machicao, A. Fritsche, H.-U. Häring, N. Stefan

Published in: Diabetologia | Issue 4/2011

Login to get access

Abstract

Aims/hypothesis

We and others recently characterised metabolically benign or healthy obesity (MHO). In the present study we investigated whether a lifestyle intervention is sufficient to place obese insulin-resistant (OIR) individuals in a position where the possible metabolic consequences are similar to those for MHO individuals.

Methods

A total of 262 non-diabetic individuals participated in a 9 month lifestyle intervention programme. Obese individuals (BMI ≥ 30.0 kg/m2) were stratified, based on their insulin sensitivity (IS) estimated from an OGTT, into MHO (IS in the upper quartile, n = 26) and OIR (IS in the lower three quartiles, n = 77). Total body and visceral fat were measured by magnetic resonance (MR) tomography and liver fat by 1H-MR spectroscopy.

Results

During the intervention, visceral fat decreased significantly in both groups (both p ≤ 0.009), whereas total body and liver fat decreased only in the OIR group (p < 0.0001; MHO p = 0.12 for total body fat and p = 0.47 for liver fat). IS improved in the OIR group (p < 0.0001), but remained essentially unchanged in the MHO group (p = 0.30). However, despite the significant increase in the OIR group, IS at follow-up barely exceeded 50% of the IS of the MHO group (OIR 9.30 ± 0.53 arbitrary units [AU]; MHO 16.41 ± 1.05 AU; p < 0.0001).

Conclusions/interpretation

IS improves during the lifestyle intervention in OIR individuals. However, it does not reach a level where adequate protection from type 2 diabetes and cardiovascular disease is expected. Thus, stratification of obese individuals based on their metabolic phenotype is important to identify those who are likely to need early pharmacological treatment in addition to the lifestyle intervention.
Literature
1.
go back to reference McLaughlin T, Abbasi F, Lamendola C, Reaven G (2007) Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 167:642–648PubMedCrossRef McLaughlin T, Abbasi F, Lamendola C, Reaven G (2007) Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 167:642–648PubMedCrossRef
2.
go back to reference Wildman RP, Muntner P, Reynolds K et al (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168:1617–1624PubMedCrossRef Wildman RP, Muntner P, Reynolds K et al (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168:1617–1624PubMedCrossRef
3.
go back to reference Meigs JB, Wilson PW, Fox CS et al (2006) Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91:2906–2912PubMedCrossRef Meigs JB, Wilson PW, Fox CS et al (2006) Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91:2906–2912PubMedCrossRef
4.
go back to reference Kloting N, Fasshauer M, Dietrich A et al (2010) Insulin sensitive obesity. Am J Physiol Endocrinol Metab 299:E506–E515PubMedCrossRef Kloting N, Fasshauer M, Dietrich A et al (2010) Insulin sensitive obesity. Am J Physiol Endocrinol Metab 299:E506–E515PubMedCrossRef
5.
go back to reference Calori G, Lattuada G, Piemonti L et al (2010) Prevalence, metabolic features and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care. doi:10.2337/dc10-0665 PubMed Calori G, Lattuada G, Piemonti L et al (2010) Prevalence, metabolic features and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care. doi:10.​2337/​dc10-0665 PubMed
6.
go back to reference Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168:1609–1616PubMedCrossRef Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168:1609–1616PubMedCrossRef
7.
go back to reference Anonymous (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. Obes Res 6(Suppl 2):51S–209S Anonymous (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. Obes Res 6(Suppl 2):51S–209S
8.
go back to reference Shin MJ, Hyun YJ, Kim OY, Kim JY, Jang Y, Lee JH (2006) Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond) 30:1529–1534CrossRef Shin MJ, Hyun YJ, Kim OY, Kim JY, Jang Y, Lee JH (2006) Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond) 30:1529–1534CrossRef
9.
go back to reference Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R (2008) Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia 51:1752–1754PubMedCrossRef Karelis AD, Messier V, Brochu M, Rabasa-Lhoret R (2008) Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia 51:1752–1754PubMedCrossRef
10.
go back to reference Arsenault BJ, Cote M, Cartier A et al (2009) Effect of exercise training on cardiometabolic risk markers among sedentary, but metabolically healthy overweight or obese post-menopausal women with elevated blood pressure. Atherosclerosis 207:530–533PubMedCrossRef Arsenault BJ, Cote M, Cartier A et al (2009) Effect of exercise training on cardiometabolic risk markers among sedentary, but metabolically healthy overweight or obese post-menopausal women with elevated blood pressure. Atherosclerosis 207:530–533PubMedCrossRef
12.
go back to reference Perseghin G (2008) Is a nutritional therapeutic approach unsuitable for metabolically healthy but obese women? Diabetologia 51:1567–1569PubMedCrossRef Perseghin G (2008) Is a nutritional therapeutic approach unsuitable for metabolically healthy but obese women? Diabetologia 51:1567–1569PubMedCrossRef
13.
go back to reference Kantartzis K, Thamer C, Peter A et al (2009) High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58:1281–1288PubMedCrossRef Kantartzis K, Thamer C, Peter A et al (2009) High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58:1281–1288PubMedCrossRef
14.
go back to reference Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470PubMedCrossRef Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470PubMedCrossRef
15.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
16.
go back to reference Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939–960PubMedCrossRef Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939–960PubMedCrossRef
17.
go back to reference Kantartzis K, Machann J, Schick F, Fritsche A, Haring HU, Stefan N (2010) The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 53:882–889PubMedCrossRef Kantartzis K, Machann J, Schick F, Fritsche A, Haring HU, Stefan N (2010) The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 53:882–889PubMedCrossRef
Metadata
Title
Effects of a lifestyle intervention in metabolically benign and malign obesity
Authors
K. Kantartzis
J. Machann
F. Schick
K. Rittig
F. Machicao
A. Fritsche
H.-U. Häring
N. Stefan
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-2006-3

Other articles of this Issue 4/2011

Diabetologia 4/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.